Patients' perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom

被引:93
|
作者
Vo, Pamela [1 ]
Fang, Juanzhi [2 ]
Bilitou, Aikaterini [3 ]
Laflamme, Annik K. [1 ]
Gupta, Shaloo [4 ]
机构
[1] Novartis Pharma AG, Fabrikstr 12, CH-4002 Basel, Switzerland
[2] Novartis Pharmaceut, One Hlth Plaza, E Hanover, NJ 07936 USA
[3] Novartis Global Serv Ctr, Patient Access Serv, Dublin, Ireland
[4] Kantar Hlth, New York, NY 10010 USA
来源
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词
Activity impairment; Burden; Healthcare resource use; Health-related quality of life; Migraine; Work impairment; QUALITY-OF-LIFE; INTERNATIONAL BURDEN; HEADACHE DISORDERS; HEALTH-CARE; EPISODIC MIGRAINEURS; DISEASE BURDEN; CO-MORBIDITY; RESOURCE USE; PREVALENCE; DISABILITY;
D O I
10.1186/s10194-018-0907-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Migraine is a distinct neurological disease that imposes a significant burden on patients, society, and the healthcare system. This study aimed to characterize the incremental burden of migraine in individuals who suffer from monthly >= 4 headache days (MHDs) by examining health-related quality of life (HRQoL), impairments to work productivity and daily activities, and healthcare resource utilization (HRU) in the EU5 (France, Germany, Italy, Spain, United Kingdom). Methods: This retrospective cross-sectional study used data from the 2016 National Health and Wellness Survey (NHWS; N = 80,600). Short-Form 36-Item Health Survey, version 2 (SF-36v2) physical and mental component summary scores (PCS and MCS), Short-form-6D (SF-6D), and EuroQoL (EQ-5D), impairments to work productivity and daily activities (Work Productivity and Activity Impairment Questionnaire (WPAI), and HRU were compared between migraine respondents suffering from >= 4 MHDs (n = 218) and non-migraine controls (n = 218) by propensity score matching using sociodemographic characteristics. Chi-square, T-tests, and Mann-Whitney tests were performed to determine significant differences between the groups after propensity score matching. Results: HRQoL was lower in migraine individuals suffering from >= 4 MHDs compared with non-migraine controls, with reduced SF-36v2 PCS (46.00 vs 50.51) and MCS (37.69 vs 44.82), SF-6D health state utility score (0.62 vs 0.71), and EQ-5D score (0.68 vs 0.81) (for all, p < 0.001). Respondents with migraine suffering from >= 4 MHDs also reported higher levels of absenteeism from work (14.43% vs 9.46%; p = 0.001), presenteeism (35.52% vs 20.97%), overall work impairment (38. 70% vs 23.27%), and activity impairment (44.17% vs 27.75%) than non-migraine controls (for all, p < 0.001). Additionally, HRU was significantly higher for individuals with MHDs compared to their matched controls. Consistently, migraine subgroups (4-7 MHDs, 8-14 MHDs and CM) had lower HRQoL, greater overall work and activity impairment, and higher HRU compared to non-migraine controls. Conclusions: Migraine of >= 4MHDs was associated with poorer HRQoL, greater work productivity loss, and higher HRU compared with non-migraine controls. The findings of the study suggest that an unmet need exists among individuals suffering from >= 4MHDs in the EU5 suggesting the need for effective prophylactic treatments to lessen the humanistic and economic burden of migraine.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom
    Pamela Vo
    Juanzhi Fang
    Aikaterini Bilitou
    Annik K. Laflamme
    Shaloo Gupta
    The Journal of Headache and Pain, 2018, 19
  • [2] The Humanistic and Economic Burden of Migraine in Europe: A Cross-Sectional Survey in Five Countries
    Doane, Michael J.
    Gupta, Shaloo
    Fang, Juanzhi
    Laflamme, Annik K.
    Vo, Pamela
    NEUROLOGY AND THERAPY, 2020, 9 (02) : 535 - 549
  • [3] Associations Between Headache-Free Days and Patient-Reported Outcomes Among Migraine Patients: A Cross-Sectional Analysis of Survey Data in Europe
    Doane, Michael J.
    Gupta, Shaloo
    Vo, Pamela
    Laflamme, Annik K.
    Fang, Juanzhi
    PAIN AND THERAPY, 2019, 8 (02) : 203 - 216
  • [4] Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom
    Eckert, Laurent
    Gupta, Shaloo
    Gadkari, Abhijit
    Mahajan, Puneet
    Gelfand, Joel M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 187 - 195
  • [5] The Humanistic and Economic Burden of Migraine in Europe: A Cross-Sectional Survey in Five Countries
    Michael J. Doane
    Shaloo Gupta
    Juanzhi Fang
    Annik K. Laflamme
    Pamela Vo
    Neurology and Therapy, 2020, 9 : 535 - 549
  • [6] Burden of Episodic and Chronic Migraine in Patients Who Had Failed Multiple Preventive Treatments From France, Spain, and the United Kingdom
    Diaz-Insa, Samuel
    Santos-Lasaosa, Sonia
    Driessen, Maurice T.
    Cohen, Joshua M.
    Lee, Lulu
    Goadsby, Peter J.
    ACTA NEUROLOGICA SCANDINAVICA, 2024, 2024 (01):
  • [7] Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey
    Kikui, Shoji
    Chen, Yirong
    Todaka, Hiroshi
    Asao, Keiko
    Adachi, Kenji
    Takeshima, Takao
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [8] A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns
    Ford, Janet H.
    Jackson, James
    Milligan, Gary
    Cotton, Sarah
    Ahl, Jonna
    Aurora, Sheena K.
    HEADACHE, 2017, 57 (10): : 1532 - 1544
  • [9] Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey
    Shoji Kikui
    Yirong Chen
    Hiroshi Todaka
    Keiko Asao
    Kenji Adachi
    Takao Takeshima
    The Journal of Headache and Pain, 2020, 21
  • [10] The burden of suicidal ideation across Europe: a cross-sectional survey in five countries
    Jaffe, Dena H.
    Rive, Benoit
    Denee, Tom R.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 2257 - 2271